Compounds of the formula ##STR00001## wherein: X is selected from the group consisting of trihalomethyl, C.sub.1-C.sub.6 alkyl, and a group of formula II: ##STR00002## wherein: R.sub.3 and R.sub.4 are independently selected from the group consisting of hydrogen; halogen; hydroxyl; nitro; C.sub.1-C.sub.6 alkyl; C.sub.1-C.sub.6 alkoxy; carboxy; C.sub.1-C.sub.6 trihaloalkyl; and cyano; Z is selected from the group consisting of substituted and unsubstituted aryl; or a pharmaceutically acceptable salt thereof. The compounds are inhibitors of cyclooxygenase-2 activity. They are useful for treating cyclooxygenase-mediated disorders, including, for example, inflamation, neoplastic disorders and angiogenesis-mediated disorders.